Results 21 to 30 of about 13,248 (184)

Genetic Dissection of Antibiotic Adjuvant Activity

mBio, 2022
Small molecule adjuvants that enhance the activity of established antibiotics represent promising agents in the battle against antibiotic resistance. Adjuvants generally act by inhibiting antibiotic resistance processes, and specifying the process acted ...
J. Bailey, L. Gallagher, W. T. Barker, V. B. Hubble, J. Gasper, C. Melander, C. Manoil   +6 more
doaj   +1 more source

Ceftazidime-avibactam

Revista Española de Quimioterapia, 2022
The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa,
openaire   +2 more sources

DataSheet1_Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis.docx

, 2021
Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384), Shanshan Long (1783180), Hao Zhou (136535), Jie Zhang (64655), Dan Li (106345), Fan Fei (1368924), Hua Yu (138267)   +6 more
core   +1 more source

Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant Mycobacterium tuberculosis

Frontiers in Pharmacology, 2021
Background: While tuberculosis (TB) is curable and preventable, the most effective first-line antibiotics cannot kill multi-drug resistant (MDR) Mycobacterium tuberculosis (Mtb).
Shashikant Srivastava, Shashikant Srivastava, Shashikant Srivastava, Tawanda Gumbo, Tania Thomas   +4 more
doaj   +1 more source

Table1_Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis.docx

, 2021
Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384), Shanshan Long (1783180), Hao Zhou (136535), Jie Zhang (64655), Dan Li (106345), Fan Fei (1368924), Hua Yu (138267)   +6 more
core   +1 more source

Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America

Microbiology Spectrum, 2022
Reports of Gram-negative bacteria harboring multiple carbapenemase genes have increased in South America, leading to an urgent need for appropriate microbiological diagnosis.
Felipe Vásquez-Ponce, Karine Dantas, Johana Becerra, Gregory Melocco, Fernanda Esposito, Brenda Cardoso, Larissa Rodrigues, Keila Lima, Aline V. de Lima, Fábio P. Sellera, Renata Mattos, Lucas Trevisoli, Marco A. Vianello, Thais Sincero, Jose Di Conza, Eliana Vespero, Gabriel Gutkind, Jorge Sampaio, Nilton Lincopan   +18 more
doaj   +1 more source

Data_Sheet_1_Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment.PDF

, 2022
This study reported the identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in a Citrobacter koseri isolated from a patient in a Chinese hospital following ceftazidime-avibactam treatment of infection caused by OXA-232 ...
Weiyi Shen (1835500), Rong Zhang (44942), Jiachang Cai (10146251), Lin Wang (11986)   +3 more
core   +1 more source

Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in Escherichia coli

Frontiers in Microbiology, 2022
Aztreonam-avibactam is a promising combination to treat carbapenem-resistant Enterobacterales including coverage for metallo-β-lactamases. Escherichia coli strains resistant to aztreonam-avibactam have emerged but resistance mechanisms remain to be ...
Ke Ma, Zhiyong Zong, Zhiyong Zong, Zhiyong Zong   +3 more
doaj   +1 more source

Presentation_1_Omic insights into various ceftazidime-avibactam-resistant Klebsiella pneumoniae isolates from two southern Italian regions.pptx

, 2023
Ceftazidime-avibactam (CZA) is one of the best therapeutic options available for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria.
Nadia Marascio (3819316), Maria Lina Mezzatesta (6178598), Angela Quirino (3413834), Giuseppe G. M. Scarlata (14330373), Grete F. Privitera (14330370), Giovanni Matera (6114287), Dalida A. Bivona (14330364), Nicolò Musso (6101027), Stefania Stefani (188822), Carlo Torti (237805), Claudia Cicino (14330367), Dafne Bongiorno (14330361), Alessandro Russo (43423), Enrico M. Trecarichi (10017149)   +13 more
core   +1 more source

Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients

Antibiotics, 2022
Metallo-beta-lactamases-producing (MBL) Enterobacterales is a growing problem worldwide. The optimization of antibiotic therapy is challenging. The pivotal available therapeutic options are either the combination of ceftazidime/avibactam and aztreonam or
Jean-François Timsit, Paul-Henri Wicky, Etienne de Montmollin   +2 more
doaj   +1 more source